Boehringer Ingelheim Pharmaceuticals recently presented results of the Phase III INPULSIS trials investigating the efficacy of OFEV® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF) at the American College of Chest Physicians Annual Meeting (CHEST 2015). The Phase III INPULSIS trials were randomized, double-blind studies designed to assess both the efficacy and safety…
OFEV® (Nintedanib) Efficacy Supported in New Study
Reata Pharmaceuticals, a clinical-stage biopharmaceutical company, recently presented results from the LARIAT trial investigating the drug bardoxolone methyl in patients with pulmonary arterial hypertension (PAH). The study entitled “Bardoxolone Methyl Evaluation in Patients with Pulmonary Arterial Hypertension (PAH)” was presented in the 2015 American College…
One of the country’s leading organizations dedicated to finding a cure for pulmonary fibrosis (PF), the Pulmonary Fibrosis Foundation (PFF), recently revealed the recipients of this year’s Established Investigator and Junior Investigator Awards. These prestigious research grants are directly supported by the Foundation’s Research Fund to Cure Pulmonary Fibrosis, and given only to…
In a recent study entitled “Down-regulation of USP13 mediates phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis,” a team of researchers investigated the differences in gene expression in fibroblast foci in patients with idiopathic pulmonary fibrosis (IPF). They found that the expression of a particular gene, USP13,…
The program for the upcoming PFF Summit 2015: From Bench to Bedside has been announced by the Pulmonary Fibrosis Foundation (PFF), the organizer of the event. The third biennial international healthcare conference on pulmonary fibrosis (PF) will take place between November 12 and 14 in Washington, D.C., and will…
ProMetic Life Sciences, Inc., a biopharmaceutical company focused on plasma-derived therapeutics and small-molecule drug development, recently announced that its product PBI-4050 for the treatment of idiopathic pulmonary fibrosis (IPF) has been granted orphan drug designation status by the European Commission. IPF is a progressive fatal lung disease of unknown…
A new study published in the journal Respiratory Research revealed that an enzyme called matrix metalloproteinase 10 may be a suitable novel biomarker for idiopathic pulmonary fibrosis (IPF). The study was led by researchers at the Kyoto University in Japan and is entitled “Matrix metalloproteinase-10:…
MediciNova Inc., a biopharmaceutical company focused on small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced the start of a Phase 2 study on its product MN-001 (tipelukast) as treatment for patients with a diagnosis of moderate to severe idiopathic pulmonary fibrosis (IPF). IPF…
ProMetic Life Sciences, Inc., a biopharmaceutical corporation active in the development of novel therapeutic products targeting unmet medical needs in several fields, including fibrosis, is pleased to announce it recently concluded a successful Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational anti-fibrotic…
Results from phase III trials with Esbriet® (pirfenidone), a drug developed by Roche, were recently presented at the European Respiratory Society (ERS) congress held in Amsterdam from September 26-30, 2015. The results revealed that Esbriet® is beneficial for long-term treatment of idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is characterized by progressive…
